Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial
- PMID: 17242315
- DOI: 10.1001/archinte.167.2.148
Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial
Abstract
Background: Despite findings that selenium supplementation may improve immune functioning, definitive evidence of its impact on human immunodeficiency virus (HIV) disease severity is lacking.
Methods: High selenium yeast supplementation (200 mug/d) was evaluated in a double-blind, randomized, placebo-controlled trial. Intention-to-treat analyses assessed the effect on HIV-1 viral load and CD4 count after 9 months of treatment. Unless otherwise indicated, values are presented as mean +/- SD.
Results: Of the 450 HIV-1-seropositive men and women who underwent screening, 262 initiated treatment and 174 completed the 9-month follow-up assessment. Mean adherence to study treatment was good (73.0% +/- 24.7%) with no related adverse events. The intention-to-treat analyses indicated that the mean change (Delta) in serum selenium concentration increased significantly in the selenium-treated group and not the placebo-treated group (Delta = 32.2 +/- 24.5 vs 0.5 +/- 8.8 microg/L; P<.001), and greater levels predicted decreased HIV-1 viral load (P<.02), which predicted increased CD4 count (P<.04). Findings remained significant after covarying age, sex, ethnicity, income, education, current and past cocaine and other drug use, HIV symptom classification, antiretroviral medication regimen and adherence, time since HIV diagnosis, and hepatitis C virus coinfection. Follow-up analyses evaluating treatment effectiveness indicated that the nonresponding selenium-treated subjects whose serum selenium change was less than or equal to 26.1 microg/L displayed poor treatment adherence (56.8% +/- 29.8%), HIV-1 viral load elevation (Delta = +0.29 +/- 1.1 log(10) units), and decreased CD4 count (Delta = -25.8 +/- 147.4 cells/microL). In contrast, selenium-treated subjects whose serum selenium increase was greater than 26.1 microg/L evidenced excellent treatment adherence (86.2% +/- 13.0%), no change in HIV-1 viral load (Delta = -0.04 +/- 0.7 log(10) units), and an increase in CD4 count (Delta = +27.9 +/- 150.2 cells/microL).
Conclusions: Daily selenium supplementation can suppress the progression of HIV-1 viral burden and provide indirect improvement of CD4 count. The results support the use of selenium as a simple, inexpensive, and safe adjunct therapy in HIV spectrum disease. Trial Registration isrctn.org Identifier: ISRCTN22553118.
Comment in
-
Does selenium supplementation slow progression of HIV? Potentially misleading presentation of the results of a trial.Arch Intern Med. 2007 Jul 23;167(14):1555-6; author reply 1557. doi: 10.1001/archinte.167.14.1555-c. Arch Intern Med. 2007. PMID: 17646614 Clinical Trial. No abstract available.
-
Selenium effects on HIV RNA and CD4 cell counts.Arch Intern Med. 2007 Jul 23;167(14):1556-7; author reply 1557. doi: 10.1001/archinte.167.14.1556. Arch Intern Med. 2007. PMID: 17646616 No abstract available.
-
Selenium and HIV-1: hope or hype?Arch Intern Med. 2007 Dec 10;167(22):2530-1. doi: 10.1001/archinte.167.22.2530-b. Arch Intern Med. 2007. PMID: 18071183 No abstract available.
Similar articles
-
[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Enferm Infecc Microbiol Clin. 2009. PMID: 19246124 Spanish.
-
A community randomized controlled clinical trial of mixed carotenoids and micronutrient supplementation of patients with acquired immunodeficiency syndrome.Eur J Clin Nutr. 2006 Nov;60(11):1266-76. doi: 10.1038/sj.ejcn.1602447. Epub 2006 May 24. Eur J Clin Nutr. 2006. PMID: 16721396 Clinical Trial.
-
Changes in HIV RNA viral load, CD4+ T-cell counts, and levels of immune activation markers associated with anti-tuberculosis therapy and cotrimoxazole prophylaxis among HIV-infected tuberculosis patients in Abidjan, Cote d'Ivoire.J Med Virol. 2005 Feb;75(2):202-8. doi: 10.1002/jmv.20257. J Med Virol. 2005. PMID: 15602734
-
Impact of acute vivax malaria on the immune system and viral load of HIV-positive subjects.Chin Med J (Engl). 2003 Dec;116(12):1810-20. Chin Med J (Engl). 2003. PMID: 14687465
-
Selenium and interleukins in persons infected with human immunodeficiency virus type 1.J Infect Dis. 2000 Sep;182 Suppl 1:S69-73. doi: 10.1086/315911. J Infect Dis. 2000. PMID: 10944486 Review.
Cited by
-
Nano-Selenium Alleviates Cd-Induced Chronic Colitis through Intestinal Flora.Nutrients. 2024 Apr 28;16(9):1330. doi: 10.3390/nu16091330. Nutrients. 2024. PMID: 38732577 Free PMC article.
-
Selenium-More than Just a Fortuitous Sulfur Substitute in Redox Biology.Molecules. 2023 Dec 24;29(1):120. doi: 10.3390/molecules29010120. Molecules. 2023. PMID: 38202704 Free PMC article. Review.
-
Association between maternal selenium levels and pregnancy outcome among human immunodeficiency virus-positive and human immunodeficiency virus-negative pregnant women in a tertiary health-care center in Owerri, Nigeria: A comparative cross-sectional study.Ann Afr Med. 2023 Jul-Sep;22(3):373-380. doi: 10.4103/aam.aam_96_22. Ann Afr Med. 2023. PMID: 37417028 Free PMC article.
-
Comparative Assessment of Serum Selenium Status in HIV-Infected and Non-infected Children: A Pilot Study in a Tertiary Hospital in Nigeria.Cureus. 2023 May 29;15(5):e39626. doi: 10.7759/cureus.39626. eCollection 2023 May. Cureus. 2023. PMID: 37388617 Free PMC article.
-
Antimicrobial and anti-viral effects of selenium nanoparticles and selenoprotein based strategies: COVID-19 and beyond.J Drug Deliv Sci Technol. 2023 Sep;86:104663. doi: 10.1016/j.jddst.2023.104663. Epub 2023 Jun 8. J Drug Deliv Sci Technol. 2023. PMID: 37362903 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous